Targeting TGFβ signal transduction for cancer therapy
Open accessThe DOI matches its Crossref record; 329 of the 330 references it cites were found in a registry or an index.
Abstract
Transforming growth factor-β (TGFβ) family members are structurally and functionally related cytokines that have diverse effects on the regulation of cell fate during embryonic development and in the maintenance of adult tissue homeostasis. Dysregulation of TGFβ family signaling can lead to a plethora of developmental disorders and diseases, including cancer, immune dysfunction, and fibrosis. In this review, we focus on TGFβ, a well-characterized family member that has a dichotomous role in cancer progression, acting in early stages as a tumor suppressor and in late stages as a tumor promoter. The functions of TGFβ are not limited to the regulation of proliferation, differentiation, apoptosis, epithelial-mesenchymal transition, and metastasis of cancer cells. Recent reports have related TGFβ to effects on cells that are present in the tumor microenvironment through the stimulation of extracellular matrix deposition, promotion of angiogenesis, and suppression of the anti-tumor immune reaction. The pro-oncogenic roles of TGFβ have attracted considerable attention because their intervention provides a therapeutic approach for cancer patients. However, the critical function of TGFβ in maintaining tissue homeostasis makes targeting TGFβ a challenge. Here, we review the pleiotropic functions of TGFβ in cancer initiation and progression, summarize the recent clinical advancements regarding TGFβ signaling interventions for cancer treatment, and discuss the remaining challenges and opportunities related to targeting this pathway. We provide a perspective on synergistic therapies that combine anti-TGFβ therapy with cytotoxic chemotherapy, targeted therapy, radiotherapy, or immunotherapy.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures







Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source says what the claim attributes to it.
In the citing paper
“TGF‐β therapeutics have recently shown great promise with the use of TGF‐β‐neutralizing antibodies and ligand traps, which inhibit the binding of TGF‐β with its receptors [155].”
From Tumor microenvironment signaling and therapeutics in cancer progression (2023) · cites this paper as [155]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Items 201–329 of 329
Structural basis of latent TGF-β1 presentation and activation by GARP on human regulatory T cells
Liénart, S., Merceron, R., Vanderaa, C., Lambert, F., Colau, D., Stockis, J., van der Woning, B., De Haard, H., Saunders, M., Coulie, P. G., et al. (2018) · Science · doi:10.1126/science.aau2909 · Cited by 153 · cited 1×
“2c).(41) Finally, integrins, which are cell adhesion receptors that control cell proliferation, survival migration, and invasion, also have a pivotal role in the activation of latent TGFβ.”
BackgroundStrauss, J., Gatti-Mays, M. E., Cho, B. C., Hill, A., Salas, S., McClay, E., Redman, J. M., Sater, H. A., Donahue, R. N., Jochems, C., et al. (2020) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2020-001395 · Cited by 153
TGF-β-induced IRAK-M expression in tumor-associated macrophages regulates lung tumor growth
Standiford, T. J., Kuick, R., Bhan, U., Chen, J., Newstead, M., & Keshamouni, V. G. (2011) · Oncogene · doi:10.1038/onc.2010.619 · Cited by 151 · cited 1×
“By inducing IRAK-M expression and antagonizing TLR signaling, TGFβ protects tumors from the potential TLR-mediated antitumor activities of macrophages.(179) TGFβ suppresses adaptive immunity during cancer progression mainly by inhibiting the activation, proliferation, differentiation, and migration of T cells.”
BackgroundTransforming Growth Factor β: Tumor Suppressor or Promoter? Are Host Immune Cells the Answer?
Yang, L., & Moses, H. L. (2008) · Cancer Research · doi:10.1158/0008-5472.can-08-2556 · Cited by 151
Yoo, C., Oh, D.-Y., Choi, H. J., Kudo, M., Ueno, M., Kondo, S., Chen, L.-T., Osada, M., Helwig, C., Dussault, I., et al. (2020) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2020-000564 · Cited by 151 · cited 1×
“Moreover, the evaluation of M7824 for patients with advanced NSCLC or biliary tract cancer is now under investigation in phase 3 clinical trials.(278,298) A recent study discovered that an anti-GARP:TGFβ1 mAb (ABBV151), which selectively blocks TGFβ1 production by Treg cells, can induce the regression of anti-PD-1 imm…”
Impairment of NKG2D-Mediated Tumor Immunity by TGF-β
Lazarova, M., & Steinle, A. (2019) · Frontiers in Immunology · doi:10.3389/fimmu.2019.02689 · Cited by 149 · cited 1×
“TGFβ blocks the activation of NK cells and suppresses their cytotoxic potential by inhibiting C-type lectin receptor NKG2D expression directly and indirectly.(177) IL1 receptor-associated kinase M (IRAKM) is a potent negative regulator of Toll-like receptor (TLR) signaling and is predominantly expressed in macrophages.”
BackgroundNemunaitis, J., Nemunaitis, M., Senzer, N., Snitz, P., Bedell, C., Kumar, P., Pappen, B., Maples, P. B., Shawler, D., & Fakhrai, H. (2009) · Cancer Gene Therapy · doi:10.1038/cgt.2009.15 · Cited by 147 · cited 1×
“Lucanix (belagenpumatucel-L) is a vaccine expressing AON TGFβ2 RNA that was evaluated in clinical trial studies for NSCLC patients.(246,247) This vaccine did not meet its survival endpoint in a phase 3 clinical trial for NSCLC patients; however, it improved the overall survival of patients who had completed chemothera…”
MethodBatlle, R., Andrés, E., Gonzalez, L., Llonch, E., Igea, A., Gutierrez-Prat, N., Berenguer-Llergo, A., & Nebreda, A. R. (2019) · Nature Communications · doi:10.1038/s41467-019-10946-y · Cited by 142 · cited 1×
“Moreover, the JNK pathway also mediates the proangiogenic response of TGFβ in endothelial cells.(167) A recent study showed that TGFβ can Fig.”
BackgroundTargeting the TGF-β1 Pathway to Prevent Normal Tissue Injury After Cancer Therapy
Anscher, M. S. (2010) · The Oncologist · doi:10.1634/theoncologist.2009-s101 · Cited by 140 · cited 1×
“Therefore, the combination of anti-TGFβ therapy with radiotherapy may improve treatment by enhancing tumor cell radiosensitivity and protecting normal tissues.(266,267) In a phase 2 clinical trial, the TGFβ-blocking antibody fresolimumab (GC1008) was combined with focal irradiation for the treatment of metastatic brea…”
Backgroundde Streel, G., Bertrand, C., Chalon, N., Liénart, S., Bricard, O., Lecomte, S., Devreux, J., Gaignage, M., De Boeck, G., Mariën, L., et al. (2020) · Nature Communications · doi:10.1038/s41467-020-17811-3 · Cited by 139 · cited 1×
“A recent study discovered that an anti-GARP:TGFβ1 mAb (ABBV151), which selectively blocks TGFβ1 production by Treg cells, can induce the regression of anti-PD-1 immunotherapy-resistant tumors in a mouse cancer model.(299,300) The phase 1 clinical trial of an antiGARP:TGFβ1 mAb (ABBV151) as monotherapy and in combinati…”
BackgroundWick, A., Desjardins, A., Suárez, C., Forsyth, P. A., Gueorguieva, I., Burkholder, T. L., Cleverly, A., Estrem, S. T., Wang, S., Lahn, M., et al. (2020) · Investigational New Drugs · doi:10.1007/s10637-020-00910-9 · Cited by 138 · cited 1×
“Phase 1/2 clinical trials of this inhibitor for patients with metastatic prostate cancer/TNBC/ advanced HCC/rectal cancer/recurrent glioblastoma are ongoing.(213,215,216) A phase 2 study of this inhibitor for patients with advanced HCC showed acceptable safety and prolonged overall survival.”
BackgroundUpregulation of two BH3-only proteins, Bmf and Bim, during TGFβ-induced apoptosis
Ramjaun, A. R., Tomlinson, S., Eddaoudi, A., & Downward, J. (2006) · Oncogene · doi:10.1038/sj.onc.1209852 · Cited by 131
LUDBROOK, S. B., BARRY, S. T., DELVES, C. J., & HORGAN, C. M. T. (2003) · Biochemical Journal · doi:10.1042/bj20020809 · Cited by 126
Bierie, B., Stover, D. G., Abel, T. W., Chytil, A., Gorska, A. E., Aakre, M., Forrester, E., Yang, L., Wagner, K.-U., & Moses, H. L. (2008) · Cancer Research · doi:10.1158/0008-5472.can-07-5597 · Cited by 124
Luo, K., & Lodish, H. F. (1996) · The EMBO Journal · doi:10.1002/j.1460-2075.1996.tb00826.x · Cited by 124
Bhowmick, N. A., Ghiassi, M., Aakre, M., Brown, K., Singh, V., & Moses, H. L. (2003) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.2536483100 · Cited by 123
Zhong, Z., Carroll, K. D., Policarpio, D., Osborn, C., Gregory, M., Bassi, R., Jimenez, X., Prewett, M., Liebisch, G., Persaud, K., et al. (2010) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-09-1634 · Cited by 123 · cited 1×
“LY3022859 is an anti-TβRII IgG1 monoclonal antibody blocking TGFβ binding to the ectodomain of TβRII that showed significant antitumor function against primary tumor growth and metastasis in several mice tumor models.(194) When tested for use in the treatment of advanced solid tumors in a phase 1 clinical trial, the m…”
BackgroundMartin, M. T., Vozenin, M., Gault, N., Créchet, F., Pfarr, C. M., & Lefaix, J.-L. (1997) · Oncogene · doi:10.1038/sj.onc.1201433 · Cited by 121 · cited 5×
“2a).3,31,36 Thrombospondin (TSP) is another activator of latent TGFβ that is present in the ECM; upon direct binding to LAP, TSP can induce the release of active TGFβ.37 In addition, the latent TGFβ binding protein (LTBP) can covalently bind to LAP, which facilitates the deposition of the SLC in the ECM and forms the…”
BackgroundInfluentialControlling Immunity and Inflammation through Integrin-Dependent Regulation of TGF-β
Nolte, M., & Margadant, C. (2020) · Trends in Cell Biology · doi:10.1016/j.tcb.2019.10.002 · Cited by 120 · cited 2×
“Previous studies showed that genetically and pharmacologically inhibition of αvβ integrin can inhibit TGFβ signaling and suppress metastasis.(201,203) For example, the cyclic RGD pentapeptide cilengitide (EMD121974) is a potent and selective inhibitor of integrin αvβ3/5 that showed a reduction of TGFβ1 and TGFβ2 messe…”
BackgroundTakeuchi, M., Kosiewicz, M. M., Alard, P., & Streilein, J. W. (1997) · European Journal of Immunology · doi:10.1002/eji.1830270709 · Cited by 119
Takasaka, N., Seed, R. I., Cormier, A., Bondesson, A. J., Lou, J., Elattma, A., Ito, S., Yanagisawa, H., Hashimoto, M., Ma, R., et al. (2018) · JCI Insight · doi:10.1172/jci.insight.122591 · Cited by 119 · cited 1×
“The engineered antibody against αvβ8 integrin can block the release of active TGFβ by cancer cells and promote the anti-tumor immune reaction in pre-clinical mice models of colon carcinoma and lung cancer.(205) A recent study showed that αvβ6-neutralizing antibody 264RAD can suppress TGFβ signaling and significantly r…”
BackgroundDas, L., & Levine, A. D. (2008) · The Journal of Immunology · doi:10.4049/jimmunol.180.3.1490 · Cited by 116
Integrin-Mediated TGFβ Activation Modulates the Tumour Microenvironment
Brown, N. F., & Marshall, J. F. (2019) · Cancers · doi:10.3390/cancers11091221 · Cited by 116 · cited 2×
“Previous studies showed that genetically and pharmacologically inhibition of αvβ integrin can inhibit TGFβ signaling and suppress metastasis.(201,203) For example, the cyclic RGD pentapeptide cilengitide (EMD121974) is a potent and selective inhibitor of integrin αvβ3/5 that showed a reduction of TGFβ1 and TGFβ2 messe…”
BackgroundTGF-β signaling in vascular biology and dysfunction
Marie-Jose, Goumans, M., Zhen, Liu, Peter, P., ten, & Dijke (2009) · Acta Scientiarum Naturalium Universitatis Sunyatseni · Cited by 116
Reader, C. S., Vallath, S., Steele, C. W., Haider, S., Brentnall, A., Desai, A., Moore, K. M., Jamieson, N. B., Chang, D., Bailey, P., et al. (2019) · The Journal of Pathology · doi:10.1002/path.5320 · Cited by 114 · cited 1×
“A recent study showed that αvβ6-neutralizing antibody 264RAD can suppress TGFβ signaling and significantly reduce tumor growth in αvβ6-positive human pancreatic ductal adenocarcinoma (PDAC) xenografts mice model and immunocompetent transgenic mice bearing αvβ6positive PDAC tumors.(206) Although most studies showed tha…”
BackgroundMcKarns, S. C., & Schwartz, R. H. (2005) · The Journal of Immunology · doi:10.4049/jimmunol.174.4.2071 · Cited by 113
The role of integrins in TGFβ activation in the tumour stroma
Khan, Z., & Marshall, J. F. (2016) · Cell and Tissue Research · doi:10.1007/s00441-016-2474-y · Cited by 113 · cited 1×
“Thus, besides their role to promote cell proliferation, survival, and migration, the ability of αv integrins to stimulate TGFβ activation contributes to cancer progression.(201,202) Thus, integrins can be pharmacological targets for cancer treatment, and their targeting may enhance the efficacy of immune therapies.”
BackgroundSow, H., Ren, J., Camps, M., Ossendorp, F., & ten Dijke, P. (2019) · Cells · doi:10.3390/cells8040320 · Cited by 112 · cited 1×
“However, despite these highly encouraging results mentioned above, we like to provide a note of caution as different tumor models with different immunogenicity can exhibit totally different, sometimes even opposite, results.(284) Some therapies in which anti-TGFβ and immunotherapy are combined have entered clinical ev…”
ResultBlocking immunosuppression by human Tregs in vivo with antibodies targeting integrin αVβ8
Stockis, J., Liénart, S., Colau, D., Collignon, A., Nishimura, S. L., Sheppard, D., Coulie, P. G., & Lucas, S. (2017) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1710680114 · Cited by 111 · cited 1×
“For example, previous research found that αvβ8 integrin-expressing tumor cells can evade host immunity by upregulating TGFβ signaling in immune cells.(204) The engineered antibody against αvβ8 integrin can block the release of active TGFβ by cancer cells and promote the anti-tumor immune reaction in pre-clinical mice…”
ResultTGF-β Antibody Uptake in Recurrent High-Grade Glioma Imaged with 89Zr-Fresolimumab PET
den Hollander, M. W., Bensch, F., Glaudemans, A. W. J. M., Munnink, T. H. O., Enting, R. H., den Dunnen, W. F. A., Heesters, M. A. A. M., Kruyt, F. A. E., Hooge, M. N. L., de Groot, J. C., et al. (2015) · Journal of Nuclear Medicine · doi:10.2967/jnumed.115.154401 · Cited by 109
Rodón, J., Carducci, M., Sepulveda-Sánchez, J. M., Azaro, A., Calvo, E., Seoane, J., Braña, I., Sicart, E., Gueorguieva, I., Cleverly, A., et al. (2015) · Investigational New Drugs · doi:10.1007/s10637-014-0192-4 · Cited by 108
Kovacs, R. J., Maldonado, G., Azaro, A., Fernández, M. S., Romero, F. L., Sepulveda-Sánchez, J. M., Corretti, M., Carducci, M., Dolan, M., Gueorguieva, I., et al. (2015) · Cardiovascular Toxicology · doi:10.1007/s12012-014-9297-4 · Cited by 108
Tolcher, A. W., Berlin, J. D., Cosaert, J., Kauh, J., Chan, E., Piha-Paul, S. A., Amaya, A., Tang, S., Driscoll, K., Kimbung, R., et al. (2017) · Cancer Chemotherapy and Pharmacology · doi:10.1007/s00280-017-3245-5 · Cited by 105 · cited 1×
“When tested for use in the treatment of advanced solid tumors in a phase 1 clinical trial, the maximum-tolerated dose for this antibody was not determined since the patients suffered from uncontrolled cytokine release despite prophylaxis.(195) Integrins are major activators of TGFβ ligand, including αvβ1, αvβ3, αvβ5,…”
BackgroundCharacterization of the latent transforming growth factor ß complex in Bone
Pfeilschifter, J., Bonewald, L., & Mundy, G. R. (1990) · Journal of Bone and Mineral Research · doi:10.1002/jbmr.5650050109 · Cited by 104 · cited 1×
“5) to dissociate the LAP portion from the mature protein.(31,32) In addition, reactive oxygen species can activate TGFβ in vitro by destroying the ability of LAP to bind to mature TGFβ via oxidative modification.”
BackgroundFujiwara, Y., Nokihara, H., Yamada, Y., Yamamoto, N., Sunami, K., Utsumi, H., Asou, H., Takahashi, O., Ogasawara, K., Gueorguieva, I., et al. (2015) · Cancer Chemotherapy and Pharmacology · doi:10.1007/s00280-015-2895-4 · Cited by 102
Current perspectives on inhibitory SMAD7 in health and disease
van Capelle, C. D. C., Spit, M., & ten Dijke, P. (2020) · Critical Reviews in Biochemistry and Molecular Biology · doi:10.1080/10409238.2020.1828260 · Cited by 102
Li, D., Qu, C., Ning, Z., Wang, H., Zang, K., Zhuang, L., Chen, L., Wang, P., & Meng, Z. (2016) · PubMed · Cited by 101
Yang, L., Chang, N., Liu, X., Han, Z., Zhu, T., Li, C., Yang, L., & Li, L. (2012) · American Journal Of Pathology · doi:10.1016/j.ajpath.2012.03.014 · Cited by 100
TGF-β and αvβ6 Integrin Act in a Common Pathway to Suppress Pancreatic Cancer Progression
Hezel, A. F., Deshpande, V., Zimmerman, S. M., Contino, G., Alagesan, B., O'Dell, M. R., Rivera, L. B., Harper, J., Lonning, S., Brekken, R. A., et al. (2012) · Cancer Research · doi:10.1158/0008-5472.can-12-0634 · Cited by 99 · cited 1×
“Although most studies showed that antiαvβ integrin therapy has promise in cancer treatment, an opposite finding was reported for antibody-mediated inhibition of αvβ6 that while leading to a strong decreased TGFβ signaling, it promoted pancreatic cancer progression.(207)”
BackgroundSaltzman, A. G., Munro, R., Searfoss, G. H., Franks, C. F., Jaye, M., & Ivashchenko, Y. (1998) · Experimental Cell Research · doi:10.1006/excr.1998.4096 · Cited by 98
Transforming growth factor β (TGFβ)-induced apoptosis: The rise and fall of Bim
Ramesh, S., Wildey, G. M., & Howe, P. H. (2009) · Cell Cycle · doi:10.4161/cc.8.1.7291 · Cited by 98
Vermorken, J. B., Peyrade, F., Krauss, J. C., Mesı́a, R., Remenár, É., Gauler, T. C., Keilholz, U., Delord, J., Schafhausen, P., Erfan, J., et al. (2014) · Annals of Oncology · doi:10.1093/annonc/mdu003 · Cited by 98
Park, I.-K., Shultz, L. D., Letterio, J. J., & Gorham, J. D. (2005) · The Journal of Immunology · doi:10.4049/jimmunol.175.9.5666 · Cited by 97
Breier, G., Blum, S., Peli, J., Groot, M., Wild, C., Risau, W., & Reichmann, E. (2002) · International Journal of Cancer · doi:10.1002/ijc.1599 · Cited by 96
Wildey, G. M., Patil, S., & Howe, P. H. (2003) · Journal of Biological Chemistry · doi:10.1074/jbc.m211958200 · Cited by 96
Schrantz, N., Bourgeade, M., Mouhamad, S., Leca, G., Sharma, S., & Vázquez, A. (2001) · Molecular Biology of the Cell · doi:10.1091/mbc.12.10.3139 · Cited by 95
Pollari, S., Leivonen, S., Perälä, M., Fey, V., Käkönen, S.-M., & Kallioniemi, O. (2012) · PLoS ONE · doi:10.1371/journal.pone.0037361 · Cited by 95
Roles of the TGF-β–VEGF-C Pathway in Fibrosis-Related Lymphangiogenesis
Kinashi, H., Ito, Y., Sun, T., Katsuno, T., & Takei, Y. (2018) · International Journal of Molecular Sciences · doi:10.3390/ijms19092487 · Cited by 93 · cited 1×
“However, the function of TGFβ in the formation of the cancer-associated lymphatic system is not well understood.(168)”
BackgroundCho, B. C., Daste, A., Ravaud, A., Salas, S., Isambert, N., McClay, E., Awada, A., Borel, C., Ojalvo, L. S., Helwig, C., et al. (2020) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2020-000664 · Cited by 90
Genetic, epigenetic, and molecular landscapes of multifocal and multicentric glioblastoma
Liu, Q., Liu, Y., Li, W., Wang, X., Sawaya, R. A., Lang, F. F., Yung, W. K. A., Chen, K., Fuller, G. N., & Zhang, W. (2015) · Acta Neuropathologica · doi:10.1007/s00401-015-1470-8 · Cited by 89
Wang, Y., Gao, Z., Du, X., Chen, S., Zhang, W., Wang, J., Li, H., He, X., Cao, J., & Wang, J. (2020) · Biomaterials Science · doi:10.1039/d0bm00916d · Cited by 88 · cited 1×
“Researchers designed pH-responsive clustered nanoparticles that can deliver TβRI kinase inhibitor galunisertib (LY2157299) and small interfering RNA targeting PD-L1 to the PDAC stroma microenvironment, and this regimen showed significant antitumor efficiency by both provoking antitumor immunity and suppressing tumor g…”
ResultAlva, A., Slovin, S., Daignault, S., Carducci, M., DiPaola, R., Pienta, K., Agus, D., Cooney, K., Chen, A., Smith, D. C., et al. (2012) · Investigational New Drugs · doi:10.1007/s10637-010-9573-5 · Cited by 87
Raguse, J.-D., Gath, H. J., Bier, J., Riess, H., & Oettle, H. (2004) · Oral Oncology · doi:10.1016/j.oraloncology.2003.08.003 · Cited by 87
Targeting TGFβR2‐mutant tumors exposes vulnerabilities to stromal TGFβ blockade in pancreatic cancer
Huang, H., Zhang, Y., Gallegos, V., Sorrelle, N., Zaid, M. M., Toombs, J., Du, W., Wright, S., Hagopian, M., Wang, Z., et al. (2019) · EMBO Molecular Medicine · doi:10.15252/emmm.201910515 · Cited by 87 · cited 2×
“5a).145,146 In turn, CAFs autocrine TGFβ can serve as an attractant to recruit more fibroblasts into the TME around the tumor invasion front and promote metastasis.147,148 CAFs surround and throughout the tumor often restrict the accessibility of anti-cancer drugs to tumor cells since the dense CAFs with stiff surroun…”
BackgroundYang, F., Strand, D. W., & Rowley, D. R. (2007) · Oncogene · doi:10.1038/sj.onc.1210663 · Cited by 86
Stevenson, J. P., Kindler, H. L., Papasavvas, E., Sun, J., Jacobs-Small, M., Hull, J., Schwed, D., Ranganathan, A., Newick, K., Heitjan, D. F., et al. (2013) · OncoImmunology · doi:10.4161/onci.26218 · Cited by 85
Tamayo, E., Álvarez, P., & Merino, R. (2018) · International Journal of Molecular Sciences · doi:10.3390/ijms19123928 · Cited by 84
A randomized phase II study of cilengitide (EMD 121974) in patients with metastatic melanoma
Kim, K. B., Prieto, V. G., Joseph, R. W., Diwan, A. H., Gallick, G. E., Papadopoulos, N. E., Bedikian, A. Y., Camacho, L. H., Hwu, P., Ng, C. S., et al. (2012) · Melanoma Research · doi:10.1097/cmr.0b013e32835312e4 · Cited by 83 · cited 1×
“However, the phase 3 clinical study of cilengitide in glioblastoma patients showed well toleration and single-agent activity.(237,238)”
BackgroundDeletion of TGF-β signaling in myeloid cells enhances their anti-tumorigenic properties
Novitskiy, S. V., Pickup, M. W., Chytil, A., Polosukhina, D., Owens, P., & Moses, H. L. (2012) · Journal of Leukocyte Biology · doi:10.1189/jlb.1211639 · Cited by 79 · cited 1×
“Indeed, experimentally induced inactivation of TGFβ signaling in myeloid cells can lead to an increase in antitumor activity.(175,176) TGFβ blocks the activation of NK cells and suppresses their cytotoxic potential by inhibiting C-type lectin receptor NKG2D expression directly and indirectly.”
BackgroundID1 Mediates Escape from TGFβ Tumor Suppression in Pancreatic Cancer
Huang, Y.-H., Hu, J., Chen, F., Lecomte, N., Basnet, H., David, C. J., Witkin, M. D., Allen, P. J., Leach, S. D., Hollmann, T. J., et al. (2020) · Cancer Discovery · doi:10.1158/2159-8290.cd-19-0529 · Cited by 78 · cited 1×
“ID1 was also shown to mediate the escape of pancreatic cancer from TGFβ tumor suppression.(81) TGFβ can increase the expression of B-cell lymphoma 2 (BCL2)-interacting mediator of cell death (BIM), BCL2-modifying factor (BMF), FAS and death-associated protein kinase (DAPK) genes and decrease the expression of BCL2 and…”
BackgroundVansteenkiste, J., Barlési, F., Waller, C. F., Bennouna, J., Gridelli, C., Goekkurt, E., Verhoeven, D., Szczęsna, A., Feurer, M., Milanowski, J., et al. (2015) · Annals of Oncology · doi:10.1093/annonc/mdv219 · Cited by 76
Chien, W. (2011) · International Journal of Oncology · doi:10.3892/ijo.2011.985 · Cited by 74
New rationales for using TGFbetainhibitors in radiotherapy
Andarawewa, K. L., Paupert, J., Pal, A., & Barcellos‐Hoff, M. H. (2007) · International Journal of Radiation Biology · doi:10.1080/09553000701711063 · Cited by 73 · cited 1×
“Therefore, the combination of anti-TGFβ therapy with radiotherapy may improve treatment by enhancing tumor cell radiosensitivity and protecting normal tissues.(266,267) In a phase 2 clinical trial, the TGFβ-blocking antibody fresolimumab (GC1008) was combined with focal irradiation for the treatment of metastatic brea…”
BackgroundMesenchymal stem cells promote tumor angiogenesis via the action of transforming growth factor β1
LI, G.-C., ZHANG, H.-W., ZHAO, Q.-C., SUN, L., YANG, J.-J., HONG, L., FENG, F., & CAI, L. (2016) · Oncology Letters · doi:10.3892/ol.2015.3997 · Cited by 72
TGF-β suppresses the upregulation of MMP-2 by vascular smooth muscle cells in response to PDGF-BB
Risinger, G. M., Updike, D. L., Bullen, E. C., Tomasek, J. J., & Howard, E. W. (2009) · American Journal of Physiology-Cell Physiology · doi:10.1152/ajpcell.00417.2008 · Cited by 70
Chae, Y. K., Pan, A. P., Davis, A. A., Patel, S. P., Carneiro, B. A., Kurzrock, R., & Giles, F. J. (2017) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-17-0597 · Cited by 70
Monoclonal antibodies as probes of integrin priming and activation
Humphries, M. J. (2004) · Biochemical Society Transactions · doi:10.1042/bst0320407 · Cited by 69
Jung, S. Y., Hwang, S., Clarke, J. M., Bauer, T. M., Keedy, V. L., Lee, H., Park, N., Kim, S.-J., & Lee, J. I. (2020) · Investigational New Drugs · doi:10.1007/s10637-019-00835-y · Cited by 69
TGF-β and Eomes control the homeostasis of CD8+ regulatory T cells
Mishra, S., Liao, W., Liu, Y., Yang, M., Ma, C., Wu, H., Zhao, M., Zhang, X., Qiu, Y., Lu, Q., et al. (2021) · Journal of Experimental Medicine · doi:10.1084/jem.20200030 · Cited by 69
T Cells Expressing Constitutively Active Akt Resist Multiple Tumor-associated Inhibitory Mechanisms
Sun, J., Dotti, G., Huye, L. E., Foster, A. E., Savoldo, B., Gramatges, M. M., Spencer, D. M., & Rooney, C. M. (2010) · Molecular Therapy · doi:10.1038/mt.2010.185 · Cited by 67 · cited 2×
“CAR T cell therapy has demonstrated remarkable success by utilizing engineered T cells with tumor antigens that lead to the recognition and attack of tumor cells in blood cancers; however, this method still remains a big challenge for treating solid tumors partially due to TGFβ-mediated immunosuppression.301 Inhibitin…”
BackgroundBradley, D., Daignault, S. D., Ryan, C. J., DiPaola, R. S., Smith, D. C., Small, E. J., Gross, M. E., Stein, M. N., Chen, A. P., & Hussain, M. (2010) · Investigational New Drugs · doi:10.1007/s10637-010-9420-8 · Cited by 61
4E‐BP1 is a target of Smad4 essential for TGFβ‐mediated inhibition of cell proliferation
Azar, R., Alard, A., Susini, C., Bousquet, C., & Pyronnet, S. (2009) · The EMBO Journal · doi:10.1038/emboj.2009.291 · Cited by 60
Cao, Y., Agarwal, R., Dituri, F., Lupo, L., Trerotoli, P., Mancarella, S., Winter, P., & Giannelli, G. (2017) · Cell Death and Disease · doi:10.1038/cddis.2017.44 · Cited by 55 · cited 1×
“Moreover, insight into stratifying tumor patients using biomarkers for selecting patients that may benefit from TGFβ targeting is urgently needed.(24,25) In this review, we”
BackgroundAn Id‐like molecule, HHM, is a synexpression group‐restricted regulator of TGF‐β signalling
Ikushima, H., Komuro, A., Isogaya, K., Shinozaki, M., Hellman, U., Miyazawa, K., & Miyazono, K. (2008) · The EMBO Journal · doi:10.1038/emboj.2008.218 · Cited by 54
Baseline T cell dysfunction by single cell network profiling in metastatic breast cancer patients
Formenti, S. C., Hawtin, R. E., Dixit, N., Evensen, E., Lee, P., Goldberg, J. D., Li, X., Vanpouille-Box, C., Schaue, D., McBride, W. H., et al. (2019) · Journal for ImmunoTherapy of Cancer · doi:10.1186/s40425-019-0633-x · Cited by 53 · cited 1×
“In a phase 2 clinical trial, the TGFβ-blocking antibody fresolimumab (GC1008) was combined with focal irradiation for the treatment of metastatic breast cancer, and it was found to prolong median overall survival and demonstrated a favorable systemic immune response.(268,269) In addition, fresolimumab (GC1008) combine…”
BackgroundIkeda, M., Takahashi, H., Kondo, S., Lahn, M. M. F., Ogasawara, K., Benhadji, K. A., Fujii, H., & Ueno, H. (2017) · Cancer Chemotherapy and Pharmacology · doi:10.1007/s00280-017-3313-x · Cited by 51
Innate Immune Cells and Their Contribution to T-Cell-Based Immunotherapy
Ginefra, P., Lorusso, G., & Vannini, N. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21124441 · Cited by 49 · cited 1×
“During tumorigenesis, myeloid cells (including myeloid-derived suppressor cells (MDSCs), macrophages, neutrophils) typically accumulate in the early stage of tumor outgrowth to suppress the T cell response and sustain an immunosuppressive environment.(169) Dendritic cells (DCs) deliver tumor antigens to T cells and na…”
BackgroundIkeda, M., Morimoto, M., Tajimi, M., Inoue, K., Benhadji, K. A., Lahn, M. M. F., & Sakai, D. (2019) · Investigational New Drugs · doi:10.1007/s10637-018-0636-3 · Cited by 46
Park, S., Seo, G., Choi, A., Stavnezer, J., & Kim, P. (2005) · European Journal of Immunology · doi:10.1002/eji.200425848 · Cited by 45
Ungerleider, N., Han, C., Zhang, J., Yao, L., & Wu, T. (2016) · Molecular Carcinogenesis · doi:10.1002/mc.22592 · Cited by 45
Bcl-2 Blocks Apoptotic Signal of Transforming Growth Factor-β in Human Hepatoma Cells
Huang, Y.-L., & Chou, C. (1998) · Journal of Biomedical Science · doi:10.1007/bf02253468 · Cited by 43
Khasraw, M., Weller, M., Lorente, D., Kolibaba, K. S., Lee, C. K., Gedye, C. A., de la Fuente, M. I., Vicente, D., Reardon, D. A., Gan, H. K., et al. (2021) · Neuro-Oncology Advances · doi:10.1093/noajnl/vdab058 · Cited by 43
NAGANUMA, H., SASAKI, A., SATOH, E., NAGASAKA, M., NAKANO, S., ISOE, S., TASAKA, K., & NUKUI, H. (1996) · Neurologia medico-chirurgica · doi:10.2176/nmc.36.789 · Cited by 42 · cited 2×
“At an early stage of cancer, TGFβ mitigates myeloid proliferation and differentiation by repressing the expression of cytokine IFNγ.(171,172) Progressively, myeloid cells in advanced-stage cancer produce TGFβ and MMPs that further inhibit antitumor immune reactions and promote tumor metastasis.”
BackgroundImmune evasion by TGFβ-induced miR-183 repression of MICA/B expression in human lung tumor cells
Trinh, T. L., Kandell, W. M., Donatelli, S. S., Tu, N., Tejera, M. M., Gilvary, D. L., Eksioglu, E. A., Burnette, A., Adams, W. A., Liu, J., et al. (2019) · OncoImmunology · doi:10.1080/2162402x.2018.1557372 · Cited by 42
Singh, J., Ling, L., Js, S., Lee, W.-C., Zhang, F. P. Y., & Jm, Y. (2004) · PubMed · Cited by 40
Flanders, K. C., Yang, Y.-A., Herrmann, M., Chen, J., Mendoza, N., Mirza, A. M., & Wakefield, L. M. (2016) · Oncotarget · doi:10.18632/oncotarget.9416 · Cited by 39 · cited 3×
“There are three highly structurally related mammalian TGFβ isoforms, that is, TGFβ1, TGFβ2, and TGFβ3.”
Ardiani, A., Gameiro, S. R., Palena, C., Hamilton, D. H., Kwilas, A., King, T. H., Schlom, J., & Hodge, J. W. (2014) · Cancer Research · doi:10.1158/0008-5472.can-13-2045 · Cited by 38 · cited 1×
“Vaccination against the EMT transcription factor TWIST1 can induce effector T cell responses and suppress murine tumor growth and spontaneous metastasis.(309) The combination of an adenovirus cancer vaccine encoding tumor-associated antigen TWIST1 (Ad-TWIST) and bifunctional fusion protein M7824 that targets both TGFβ…”
BackgroundChen, Z., Li, D., Tong, L. H. T., Stewart, P. A., Chu, C., & Pflugfelder, S. C. (2006) · PubMed · Cited by 33
A phase I study of continuous infusion cilengitide in patients with solid tumors
O’Donnell, P. H., Undevia, S. D., Stadler, W. M., Karrison, T. M., Nicholas, M. K., Janisch, L. A., & Ratain, M. J. (2010) · Investigational New Drugs · doi:10.1007/s10637-010-9537-9 · Cited by 33
Regulation of the TGF-β pathway by deubiquitinases in cancer
Liu, S., de Boeck, M., van Dam, H., & ten Dijke, P. (2016) · The International Journal of Biochemistry & Cell Biology · doi:10.1016/j.biocel.2016.05.001 · Cited by 33
Keedy, V. L., Bauer, T. M., Clarke, J. M., Hurwitz, H., Baek, I., Ha, I., Ock, C.-Y., Nam, S. Y., Kim, M., Park, N., et al. (2018) · Journal of Clinical Oncology · doi:10.1200/jco.2018.36.15_suppl.3031 · Cited by 33 · cited 1×
“This inhibitor displayed a favorable safety profile and antitumor efficacy in phase 1 clinical trials for patients with advanced solid tumors or desmoid tumors.(219,220) Phase 1 clinical trial investigation of this inhibitor for patients with refractory multiple myeloma/metastatic CRC/ metastatic PDAC and phase 2 stud…”
BackgroundKang, S. H., Bang, Y.-J., Jong, H.-S., Seo, J., Kim, N., & Kim, S.-J. (1999) · British Journal of Cancer · doi:10.1038/sj.bjc.6690478 · Cited by 31
Capper, D., von Deimling, A., Brandes, A. A., Carpentier, A., Kesari, S., Sepúlveda-Sánchez, J. M., Wheeler, H., Chinot, O. L., Cher, L., Steinbach, J. P., et al. (2017) · International Journal of Molecular Sciences · doi:10.3390/ijms18050995 · Cited by 31
Hartley, J., & Abken, H. (2019) · Clinical & Translational Immunology · doi:10.1002/cti2.1064 · Cited by 31 · cited 1×
“In addition, the unsuccessful antitumor activity of chimeric antigen receptor (CAR) T cell therapy has been attributed in part to TGFβ-induced immunosuppression.(277) Because of these insights into TGFβ’s immunosuppressive function, the combination of antiTGFβ therapy and immunotherapy is under intensive investigation.”
BackgroundVallières, L. (2009) · PubMed · Cited by 30
Addressing cancer signal transduction pathways with antisense and siRNA oligonucleotides
Juliano, R. L. (2020) · NAR Cancer · doi:10.1093/narcan/zcaa025 · Cited by 30 · cited 1×
“Antisense oligonucleotides AONs are short oligonucleotides designed to suppress the expression of specific genes by blocking their translation.(239) Trabedersen (AP12009) is a phosphonothioate antisense oligodeoxynucleotide that specifically targets TGFβ2 mRNA.”
BackgroundLin, H., Huang, C.-C., Ou, Y.-C., Huang, E.-Y., ChangChien, C.-C., Tseng, C.-W., Fu, H.-C., Wu, C.-H., Li, C.-J., & Ma, Y.-Y. (2012) · International Journal of Gynecological Pathology · doi:10.1097/pgp.0b013e31824c23a4 · Cited by 28 · cited 1×
“A positive correlation between the TGFβ level and microvessel density was observed in various types of tumors.(159) Endothelial cells express two TβRIs (activin receptor-like kinase 1 (ALK1) and TβRI/ALK5).”
BackgroundAbstract 955: LY3200882, a novel, highly selective TGFβRI small molecule inhibitor
Pei, H., Parthasarathy, S., Joseph, S., McMillen, W., Xu, X., Castaneda, S., Inigo, I., Britt, K., Anderson, B., Zhao, G., et al. (2017) · Cancer Research · doi:10.1158/1538-7445.am2017-955 · Cited by 28
Study of interaction between Smad7 and DNA by single-molecule force spectroscopy
Shi, X., Chen, F., Yu, J., Xu, Y., Zhang, S., Chen, Y., & Fang, X. (2008) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2008.10.145 · Cited by 27 · cited 1×
“SMAD7 can also antagonize TGFβ signaling in the nucleus by disrupting the formation of the functional SMAD–DNA complex.(60,61) Moreover, SMAD7 recruits E3 ubiquitin ligases such as SMAD ubiquitination regulatory factor 1/2 (SMURF1/2), WW domain-containing protein 1 (WWP1), and neural precursor cellexpressed developmen…”
BackgroundOettle, H., Hilbig, A., Seufferlein, T., Tsianakas, A., Luger, T. A., Schmid, R. M., von Wichert, G., Endlicher, E., Garbe, C., Kaehler, K. C., et al. (2011) · Journal of Clinical Oncology · doi:10.1200/jco.2011.29.15_suppl.2513 · Cited by 26 · cited 1×
“Trabedersen was evaluated in the phase 1 clinical studies in patients with melanoma/pancreatic cancer/CRC, and showed good safety and encouraging survival results.(241) The phase 2 clinical trials’ evaluation of this AON for patients with glioblastoma or anaplastic astrocytoma enabled the determination of the optimal…”
MethodMassabeau, C., Khalifa, J., Filleron, T., Modesto, A., Bigay-Game, L., Plat, G., Dierickx, L., Aziza, R., Rouquette, I., Gomez‐Roca, C., et al. (2017) · Clinical Lung Cancer · doi:10.1016/j.cllc.2017.11.002 · Cited by 26
Yap, T. A., Lakhani, N. J., Araujo, D. V., Rodon Ahnert, J., Chandana, S. R., Sharma, M., Denis, J.-F., Gruosso, T., Tremblay, G., O'Connor, M., et al. (2020) · Journal of Clinical Oncology · doi:10.1200/jco.2020.38.15_suppl.3587 · Cited by 26
Development and validation of a phosphorylated SMADex vivostimulation assay
Farrington, D. L., Yingling, J. M., Fill, J. A., Yan, L., Qian, Y.-W., Shou, J., Wang, X., Ehsani, M. E., Cleverly, A., Daly, T. M., et al. (2007) · Biomarkers · doi:10.1080/13547500601162441 · Cited by 22 · cited 1×
“Moreover, insight into stratifying tumor patients using biomarkers for selecting patients that may benefit from TGFβ targeting is urgently needed.(24,25) In this review, we”
BackgroundKopetz, S., Spira, A. I., Wertheim, M. S., Kim, E. J.-H., Tan, B. R., Lenz, H., Nikolinakos, P. G., Rich, P., Smith, D. A. B., Helwig, C., et al. (2018) · Journal of Clinical Oncology · doi:10.1200/jco.2018.36.4_suppl.764 · Cited by 16
Strauss, J., Gatti-Mays, M. E., Cho, B., Salas, S., McClay, E. F., Redman, J. M., Sater, H. A., Donahue, R. N., Lamping, E., Burmeister, A., et al. (2019) · Cancer Research · doi:10.1158/1538-7445.am2019-ct075 · Cited by 16 · cited 1×
“M7824 has also been combined with the HPV vaccine PRGN-2009 in phase 1/2 clinical trials for subjects with HPV-associated cancers (NCT04432597) and combined with cancer vaccines that target the EMT driver transcription factor brachyury in phase 1/2 clinical trials for patients with advanced breast cancer (NCT04296942)…”
MethodBerlin, J. D., Harb, W. A., Adjei, A. A., Xing, Y., Swiecicki, P. L., Seetharam, M., Nandagopal, L., Gopal, A. K., Xu, C., Xu, C., et al. (2020) · Regular and Young Investigator Award Abstracts · doi:10.1136/jitc-2020-sitc2020.0385 · Cited by 16
Enhancing Cancer Vaccine Efficacy via Modulation of the Tumor Microenvironment
Disis, M. L. (2009) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-09-2256 · Cited by 15 · cited 1×
“Anti-TGFβ therapy can also be combined with cancer vaccines to enhance treatment efficacy.(308) Vaccination against the EMT transcription factor TWIST1 can induce effector T cell responses and suppress murine tumor growth and spontaneous metastasis.”
BackgroundPaz-Ares, L. G., Kim, T. M., Baz, D. V., Felip, E., Lee, D. H., Lee, K. H., Lin, C., Nicola, M. A. D., Alvarez, R. M., Dussault, I., et al. (2018) · Journal of Clinical Oncology · doi:10.1200/jco.2018.36.15_suppl.9017 · Cited by 14
Galunisertib enhances chimeric antigen receptor-modified T cell function
Wang, Z., Liu, Q., Na, R., Fu, J., Zou, Y., Tang, J., Li, L., Liu, H., Guo-min, Z., & Zhu, X. (2020) · European Journal of Histochemistry · doi:10.4081/ejh.2020.3122 · Cited by 14 · cited 1×
“Inhibiting TGFβ signaling in CART cells can boost their antitumor efficacy in solid tumors.(302,303) Other strategies also reported overcoming CART cell repression by interfering with TGFβ signaling, such as coexpression of the dominant-negative TβRII,(304) coexpression of TβRII-41BB to switch the TGFβ-suppressive sig…”
BackgroundYap, T. A., Araújo, D. V., Wood, D. L., Denis, J.-F., Gruosso, T., Tremblay, G., O'Connor‐McCourt, M. D., Ghosh, R., Sinclair, S., Nadler, P. I., et al. (2020) · Poster presentations · doi:10.1136/lba2019.10 · Cited by 12
Bogdahn, U., Schneider, T., Oliushine, V. E., Парфенов, В. Е., Mahapatra, A. K., Balasubramaniam, A., Venkataramana, N. K., Stockhammer, G., Heinrichs, H., & Schlingensiepen, K.-H. (2009) · Journal of Clinical Oncology · doi:10.1200/jco.2009.27.15_suppl.2037 · Cited by 11
Kim, B.-G., Choi, S. H., Luo, G., Sergeeva, O., Lee, Z., Driscoll, J. J., Lima, M. J. G. D., Beck, R. C., Kim, S., Letterio, J. J., et al. (2018) · Blood · doi:10.1182/blood-2018-99-117852 · Cited by 9 · cited 1×
“Vactosertib (TEW-7197) is another orally bioavailable kinase inhibitor of TβRI that revealed promising antitumor function in a mouse model of myeloma.(218) This inhibitor displayed a favorable safety profile and antitumor efficacy in phase 1 clinical trials for patients with advanced solid tumors or desmoid tumors.”
BackgroundJung, M., Lee, C., Kim, H. S., Ock, C., Bum, B. J., Lee, J., Kang, D. W., Hwang, S.-J., Kim, S. J., Chung, H. C., et al. (2020) · Journal of Clinical Oncology · doi:10.1200/jco.2020.38.15_suppl.e16505 · Cited by 9
Kim, H. S., Ahn, J., Kim, J. E., Hong, J. Y., Lee, J., Kim, S. H., Lee, J., Hwang, S.-J., Jeon, M. K., & Kim, S. (2020) · Journal of Clinical Oncology · doi:10.1200/jco.2020.38.15_suppl.11557 · Cited by 8
Effect of the integrin inhibitor cilengitide on TGF-beta signaling.
Weller, M., Silginer, M., Goodman, S. L., Hasenbach, K., Thies, S., Schraml, P., Tabatabai, G., Moch, H., Tritschler, I., & Roth, P. (2012) · Journal of Clinical Oncology · doi:10.1200/jco.2012.30.15_suppl.2055 · Cited by 7 · cited 2×
“The intracranial LN-308 glioma xenograft mice model also displayed decreased SMAD2 phosphorylation in response to cilengitide.(226) This inhibitor has been evaluated in phase 1 clinical trials for patients with brain tumors/lung cancer/advanced solid tumor/lymphoma/ HIV-related Kaposi’s sarcoma; in phase 2 clinical tr…”
BackgroundMethodO'Connor‐McCourt, M. D., Lenferink, A. E. G., Zwaagstra, J. C., Sulea, T. I., Collins, C., Singh, R., Durocher, Y., Cantin, C., & Koropatnick, J. D. (2017) · Cancer Research · doi:10.1158/1538-7445.am2017-4688 · Cited by 7
Lan, Y., Zhang, D., Xu, C., Marelli, B., Qi, J., Qi, H., Qin, G., Xu, X., Wang, H., Sircar, A., et al. (2017) · Cancer Research · doi:10.1158/1538-7445.am2017-2615 · Cited by 7 · cited 2×
“NIS793 is a monoclonal antibody blocking TGFβ1 and TGFβ2 and is being tested in combination with the anti-PD1 antibody PDR001 in a phase 1 clinical trial of patients with advanced malignancies (NCT02947165).262 M7824 is a bifunctional fusion protein consisting of the ectodomain of TβRII, which serves as a TGFβ ligand…”
BackgroundAhn, M., Barlési, F., Felip, E., Garon, E. B., Martin, C. M., Mok, T. S. K., Vokes, E. E., Ojalvo, L. S., Köenig, A., Dussault, I., et al. (2019) · Journal of Clinical Oncology · doi:10.1200/jco.2019.37.15_suppl.tps9114 · Cited by 7
Hwang, L., Ng, K., Wang, W., & Trieu, V. N. (2016) · Cancer Research · doi:10.1158/1538-7445.am2016-3742 · Cited by 5
Stevenson, J. P., Kindler, H. L., Schwed, D., Ranganathan, A., Jacobs-Small, M., Shouldis, J., Marshall, A., Heitjan, D. F., Langer, C. J., Hsu, F. J., et al. (2012) · Journal of Clinical Oncology · doi:10.1200/jco.2012.30.15_suppl.7077 · Cited by 5
Gregory, R. C., Greco, R., Qu, H., Malkova, N. V., Levit, M. N., Perron, K., Racki, W. J., Sun, F., Shapiro, G., Winter, C. G., et al. (2018) · Cancer Research · doi:10.1158/1538-7445.am2018-2790 · Cited by 5 · cited 1×
“SAR439459 is a pan-TGFβ ligand-neutralizing antibody, and the combination of SAR439459 and anti-PD1 antibody lead to tumor regression in the MC38 tumor-bearing mice model.(287) SAR439459 in combination with the anti-PD1 antibody cemiplimab is now being tested in a phase 1 clinical trials for patients with advanced sol…”
BackgroundAllan, S., Braiteh, F., Calvo, E., Cervantes, A. M. R., Edenfield, W. J., Li, T., Rasschaert, M., Park-Simon, T., Longo, F., Paz-Ares, L. G., et al. (2019) · International Journal of Gynecological Cancer · doi:10.1136/ijgc-2019-esgo.100 · Cited by 4
Borad, M. J., Javle, M. M., Furuse, J., Hsu, C., Moehler, M. H., Oh, D., Park, J. O., Shen, L., Valle, J. W., Li, M., et al. (2019) · HepatoBiliary Surgery and Nutrition · doi:10.21037/hbsn.2019.ab052 · Cited by 3
Gatti-Mays, M. E., Palena, C., Gameiro, S. R., Donahue, R. N., Jochéms, C., Steinberg, S. M., Lipkowitz, S., Zimmer, A. S., Francis, D. C., Strauss, J., et al. (2020) · Cancer Research · doi:10.1158/1538-7445.sabcs19-ot1-08-01 · Cited by 3
Phase I Trials in Pancreatic Cancer
Seufferlein, T. T. W., Kestler, A. M. R., Beutel, A. K., Perkhofer, L., & Ettrich, T. J. (2020) · Molecular and translational medicine · doi:10.1007/978-3-030-49476-6_15 · Cited by 3
Khasraw, M., Weller, M., Estelles, D. L., Kolibaba, K. S., Lee, C. K., Gedye, C. A., de la Fuente, M. I., Vicente, D., Reardon, D. A., Ojalvo, L. S., et al. (2018) · Neuro-Oncology · doi:10.1093/neuonc/noy148.011 · Cited by 2
Effect of adjuvant radiation on survival for extra-hepatic cholangiocarcinoma.
Takahashi, C., Shridhar, R., Huston, J., Patel, A. J., Brown, R. H., Koehler, K., Briceno, P., & Meredith, K. L. (2018) · Journal of Clinical Oncology · doi:10.1200/jco.2018.36.4_suppl.377 · Cited by 1
Redman, J. M., Steinberg, S. M., & Gulley, J. L. (2018) · Journal of Clinical Oncology · doi:10.1200/jco.2018.36.15_suppl.tps3130 · Cited by 1 · cited 1×
“M7824 has also been combined with the HPV vaccine PRGN-2009 in phase 1/2 clinical trials for subjects with HPV-associated cancers (NCT04432597) and combined with cancer vaccines that target the EMT driver transcription factor brachyury in phase 1/2 clinical trials for patients with advanced breast cancer (NCT04296942)…”
MethodGarland, R. J., Kirkham, C., Yap, M., Brackenbury, L. S., Iannitti, T., Nunan, R., & Jenkinson, S. (2020) · Regular and Young Investigator Award Abstracts · doi:10.1136/jitc-2020-sitc2020.0006 · Cited by 1
Research works printed but not linked: 3
- Derynck, R., Muthusamy, B. P. & Saeteurn, K. Y. Signaling pathway cooperation in TGF-β-induced epithelial-mesenchymal transition. Curr. Opin. Cell Biol. 31, 56–66 (2014). · DOI · Paper page
- Kim, H. S. et al. A phase I study of TGF-β inhibitor, vactosertib in combination with imatinib in patients with advanced desmoid tumor (aggressive fibromatosis). J. Clin. Oncol. 38, e11557 (2020). · DOI
- Derynck, R. & Budi, E. H. J. Ss Specificity, versatility, and control of TGF-β family signaling. Sci. Signal 12, eaav5183 (2019). · DOI · Paper page
Cited by
Targeting TGF-β signal transduction for fibrosis and cancer therapy
Peng, D., Fu, M., Wang, M., Wei, Y., & Wei, X. (2022) · Molecular Cancer · doi:10.1186/s12943-022-01569-x · Cited by 1,065
“In recent years, scientists found that overexpressed TGF-β causes a plethora of metabolic disorders and dysfunction, and promotes epithelial-mesenchymal transition (EMT) and excessive deposition of ECM [5, 6], which causes immune dysfunction, fibrosis, and cancers [7].”
BackgroundHarnessing cytokines and chemokines for cancer therapy
Propper, D. J., & Balkwill, F. R. (2022) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-021-00588-9 · Cited by 989
Dynamic EMT: a multi‐tool for tumor progression
Brabletz, S., Schuhwerk, H., Brabletz, T., & Stemmler, M. P. (2021) · The EMBO Journal · doi:10.15252/embj.2021108647 · Cited by 761
Radiotherapy combined with immunotherapy: the dawn of cancer treatment
Zhang, Z., Liu, X., Chen, D., & Yu, J. (2022) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-022-01102-y · Cited by 670
Zhang, M., Ma, Y., Ye, X., Zhang, N., Pan, L., & Wang, B. (2023) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-023-01464-x · Cited by 522
Metadata
- Authors
- Liu, S., Ren, J., & ten Dijke, P.
- Affiliations
- Leiden University Medical Center (NL)
- ORCID
- Liu, Sijia
- Venue
- Signal Transduction and Targeted Therapy
- Published
- 2021-01-08
- Volume
- 6
- Issue
- 1
- Pages
- 8-8
- ISSN
- 2059-3635 (ISSN-L)
- PMC
- PMC7791126
- OpenAlex
- W3119664087
- Cited by
- 413
- References
- 330
- Citations by year
- 2026: 56 · 2025: 95 · 2024: 89 · 2023: 74 · 2022: 58 · 2021: 41
- FWCI
- 7.19
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Licence
- cc-by
- creativecommons.org/licenses/by/4.0 (tdm)
- creativecommons.org/licenses/by/4.0 (vor)
- Locations
- Signal Transduction and Targeted Therapy (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- Leiden Repository (Leiden University) (submittedVersion, cc-by)
- Data Archiving and Networked Services (DANS) (submittedVersion, cc-by)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
- Funders
- Cancer Genomics Centre
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › TGF-β signaling in diseases
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Kruppel-like factors research
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Mechanisms of cancer metastasis
- Keywords
- TGF-beta signaling, cancer therapy, tumor suppressor, tumor promoters, epithelial-mesenchymal transition, metastasis, tumor microenvironment, extracellular matrix deposition, angiogenesis, combination therapy, chemotherapy, targeted therapy, radiotherapy, immunotherapy
- MeSH terms
- Humans, Neoplasm Proteins, Neoplasms, Signal Transduction, Transforming Growth Factor beta, Epithelial-Mesenchymal Transition, Tumor Microenvironment, Carcinogenesis
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.